Aug 18, 2026 · 6 min
Klarna slides as Fabrinet falls despite beating estimates
Klarna Plunges, Amylyx Pharma Soars, Bath & Body Works Rallies
The episode contrasts a guidance-driven selloff with a post-earnings decline, showing how leadership changes and profit-taking can reshape market reactions.
- 1Klarna plunged 18% pre-market after lowering revenue expectations and undergoing leadership changes.
- 2Fabrinet dropped 11% despite beating Wall Street targets, with profit-taking cited as a likely factor.
- 3Alexis Christophorous frames both moves as examples of markets looking beyond headline earnings results.
Don't miss
Fabrinet’s 11% drop despite beating Wall Street expectations is the episode’s clearest market paradox.
The brief
Stock Movers opens with a sharp contrast in market reactions: Klarna plunges before the open after lowering revenue expectations and undergoing leadership changes.
Alexis Christophorous examines Klarna’s 18% pre-market drop, where weaker guidance and a leadership reset outweighed the company’s broader market profile.
The discussion then turns to Fabrinet, whose shares fell 11% despite beating Wall Street targets, a move likely driven by investors taking profits.
Together, the two declines show why earnings headlines alone do not determine a stock’s direction: expectations, guidance and positioning can matter just as much.
What was said on this episode
3 statements · 3 positive
Amylyx’s experimental drug could generate billions in revenue
“they're saying revenue could be in the billions of dollars”
Listen at 2:19
Citi recommends buying Bath & Body Works shares
“Citi is raising the recommendation on Bath and Body Works to buy from neutral”
Listen at 3:16
Bath & Body Works has a favorable risk-reward outlook
“they are citing a favorable risk reward outlook”
Listen at 3:21
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.